7-Methylbenzo[d]isoxazol-3-amine | 1699584-90-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 7-Methylbenzo[d]isoxazol-3-amine
• 英文别名: 7-methyl-1,2-benzoxazol-3-amine
• CAS: 1699584-90-1
• 化学式: C₈H₈N₂O
• 分子量: 148.16
• InChiKey: HSNPIDUOHGWFIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20110207713A1

  公开（公告）日：2011-08-25

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I 化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制 PI3K 的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用 Formula I 化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病，或相关病理条件的方法。
• [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2015160636A1

  公开（公告）日：2015-10-22

  In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  在其多种实施方式中，本发明提供了一类新型的苯甲酰胺化合物，其由式（I）表示，或者其药用可接受的盐或溶剂，或者包含一种或多种所述化合物或其药用可接受的盐或溶剂的药物组合物，并提供了使用所述化合物或其药用可接受的盐或溶剂来治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
• METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND
  申请人：Miki Takashi

  公开号：US20120123122A1

  公开（公告）日：2012-05-17

  The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.

  本发明涉及一种制备硼酸酯化合物的方法，其特征在于在氮含有机碱、镍催化剂、膦化合物和溶剂的存在下，将芳基卤化物化合物和二硼酯化合物反应。根据本发明的制造方法，即使使用镍催化剂作为催化剂，也可以获得所需的硼酸酯化合物，产率足够高。此外，即使使用价格较低且反应性较低的芳基氯化物或芳基溴化物作为芳基卤化物化合物，也可以获得所需的硼酸酯化合物，产率足够高。
• [EN] CAPSID INHIBITORS FOR THE TREATMENT OF HIV<br/>[FR] INHIBITEURS DE CAPSIDE POUR LE TRAITEMENT DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2021262990A1

  公开（公告）日：2021-12-30

  The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

  本公开涉及一些化合物，包括所述化合物的药物组合物，以及制备和使用所述化合物和药物组合物的方法。本文披露的化合物和组合物可用于治疗或预防Retroviridae病毒感染，包括由HIV病毒引起的感染。
• PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20090318411A1

  公开（公告）日：2009-12-24

  Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的嘌呤化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，可用于抑制脂质激酶，包括p110 alpha和其他PI3K同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。